犬类减肥药地洛他得应该复活吗？

IF 1.4 3区农林科学 Q2 VETERINARY SCIENCES

American journal of veterinary research Pub Date : 2025-08-29 DOI:10.2460/ajvr.25.05.0175

Matthew R Krecic

{"title":"犬类减肥药地洛他得应该复活吗？","authors":"Matthew R Krecic","doi":"10.2460/ajvr.25.05.0175","DOIUrl":null,"url":null,"abstract":"The antiobesity canine drug dirlotapide, a selective microsomal triglyceride transfer protein inhibitor, was available from 2007 through 2010. Managing dogs on dirlotapide was labor intensive, and gastrointestinal side effects were unacceptable to dog owners. However, given the current popularity of glucagon-like peptide-1 agonists and increasing familiarity with their dosing and associated gastrointestinal side effects, dog owners may now be more accepting of dirlotapide.","PeriodicalId":7754,"journal":{"name":"American journal of veterinary research","volume":" ","pages":"1-3"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Should the canine weight-loss drug dirlotapide be resurrected?\",\"authors\":\"Matthew R Krecic\",\"doi\":\"10.2460/ajvr.25.05.0175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The antiobesity canine drug dirlotapide, a selective microsomal triglyceride transfer protein inhibitor, was available from 2007 through 2010. Managing dogs on dirlotapide was labor intensive, and gastrointestinal side effects were unacceptable to dog owners. However, given the current popularity of glucagon-like peptide-1 agonists and increasing familiarity with their dosing and associated gastrointestinal side effects, dog owners may now be more accepting of dirlotapide.\",\"PeriodicalId\":7754,\"journal\":{\"name\":\"American journal of veterinary research\",\"volume\":\" \",\"pages\":\"1-3\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of veterinary research\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.2460/ajvr.25.05.0175\",\"RegionNum\":3,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of veterinary research","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.2460/ajvr.25.05.0175","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

抗肥胖犬用药物地洛他啶是一种选择性微粒体甘油三酯转移蛋白抑制剂，于2007年至2010年上市。用地洛他啶管理狗是劳动密集型的，而且对狗主人来说，胃肠道副作用是不可接受的。然而，考虑到目前胰高血糖素样肽-1激动剂的流行，以及对其剂量和相关胃肠道副作用的日益熟悉，狗主人现在可能更接受地洛他啶。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Should the canine weight-loss drug dirlotapide be resurrected?

The antiobesity canine drug dirlotapide, a selective microsomal triglyceride transfer protein inhibitor, was available from 2007 through 2010. Managing dogs on dirlotapide was labor intensive, and gastrointestinal side effects were unacceptable to dog owners. However, given the current popularity of glucagon-like peptide-1 agonists and increasing familiarity with their dosing and associated gastrointestinal side effects, dog owners may now be more accepting of dirlotapide.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American journal of veterinary research 农林科学-兽医学

CiteScore

1.70

自引率

10.00%

发文量

186

审稿时长

3 months

期刊介绍： The American Journal of Veterinary Research supports the collaborative exchange of information between researchers and clinicians by publishing novel research findings that bridge the gulf between basic research and clinical practice or that help to translate laboratory research and preclinical studies to the development of clinical trials and clinical practice. The journal welcomes submission of high-quality original studies and review articles in a wide range of scientific fields, including anatomy, anesthesiology, animal welfare, behavior, epidemiology, genetics, heredity, infectious disease, molecular biology, oncology, pharmacology, pathogenic mechanisms, physiology, surgery, theriogenology, toxicology, and vaccinology. Species of interest include production animals, companion animals, equids, exotic animals, birds, reptiles, and wild and marine animals. Reports of laboratory animal studies and studies involving the use of animals as experimental models of human diseases are considered only when the study results are of demonstrable benefit to the species used in the research or to another species of veterinary interest. Other fields of interest or animals species are not necessarily excluded from consideration, but such reports must focus on novel research findings. Submitted papers must make an original and substantial contribution to the veterinary medicine knowledge base; preliminary studies are not appropriate.